Literature DB >> 11532532

SPECT and neuropsychological performance in severe depression treated with ECT.

E Mervaala1, M Könönen, J Föhr, M Husso-Saastamoinen, M Valkonen-Korhonen, J T Kuikka, H Viinamäki, A K Tammi, J Tiihonen, J Partanen, J Lehtonen.   

Abstract

BACKGROUND: In severe depression, studies of regional cerebral blood flow (rCBF) by SPECT have not produced uniform results. The association between changes in SPECT and electroconvulsive therapy (ECT) has shown somewhat conflicting data. No data are available on benzodiazepine receptor function SPECT studies in ECT.
METHODS: Twenty drug-resistant adult inpatients fulfilling the DSM-IIIR criteria for major depression were studied by SPECT (rCBF by relative ECD uptake in all, and benzodiazepine receptor function by iomazenil uptake in five subjects) before and 1 week after clinically successful bitemporal ECT. Clinical and neuropsychological test scores were used as references for the possible changes in SPECT.
RESULTS: An increased perfusion after ECT was observed in right temporal and bilateral parietal cortices, whereas no reductions in relative ECD uptake were seen after ECT. Iomazenil-SPECT revealed a highly significant increase in the benzodiazepine receptor uptake in all studied cortical regions except temporal cortices.
CONCLUSIONS: Clinically successful ECT was associated with changes in vascular perfusion and GABAergic neurotransmission, providing new evidence for the mechanism of action of ECT and for the neurobiology of severe drug-resistant depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532532     DOI: 10.1016/s0165-0327(00)00288-3

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  13 in total

Review 1.  [Value of diagnostic imaging in evaluation of electroconvulsive therapy].

Authors:  T Frodl; E M Meisenzahl; H-J Möller
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

2.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

3.  Long lasting effects of electroconvulsive seizures on brain oxidative parameters.

Authors:  Gustavo Feier; Luciano K Jornada; Tatiana Barichello; Angeles M Vitali; Fernanda Bonatto; José Cláudio F Moreira; Felipe Dal-Pizzol; João Quevedo
Journal:  Neurochem Res       Date:  2006-05-23       Impact factor: 3.996

Review 4.  Potential Mechanisms Underlying the Therapeutic Effects of Electroconvulsive Therapy.

Authors:  Jiangling Jiang; Jijun Wang; Chunbo Li
Journal:  Neurosci Bull       Date:  2016-12-28       Impact factor: 5.203

5.  [Vagus nerve stimulation, repetitive transcranial magnetic stimulation, and electroconvulsive therapy in the treatment of depressive disorders].

Authors:  M Bajbouj; I Heuser
Journal:  Nervenarzt       Date:  2005-01       Impact factor: 1.214

Review 6.  Central GABAergic systems and depressive illness.

Authors:  G Tunnicliff; E Malatynska
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

7.  Structure-related oxidative damage in rat brain after acute and chronic electroshock.

Authors:  T Barichello; F Bonatto; F R Agostinho; A Reinke; J C F Moreira; F Dal-Pizzol; I Izquierdo; J Quevedo
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

8.  Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.

Authors:  Ursula M H Klumpers; Dick J Veltman; Madeleine L Drent; Ronald Boellaard; Emile F I Comans; Gerben Meynen; Adriaan A Lammertsma; Witte J G Hoogendijk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-05       Impact factor: 9.236

Review 9.  Electroconvulsive therapy and its different indications.

Authors:  Thomas C Baghai; Hans-Jürgen Möller
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

10.  Pre-treatment amygdala volume predicts electroconvulsive therapy response.

Authors:  Freek Ten Doesschate; Philip van Eijndhoven; Indira Tendolkar; Guido A van Wingen; Jeroen A van Waarde
Journal:  Front Psychiatry       Date:  2014-11-26       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.